Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allovir Inc (NQ: ALVR )

3.930 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.930
Bid (Size) 2.500 (1)
Ask (Size) 6.730 (1)
Prev. Close 3.930
Today's Range 3.930 - 3.930
52wk Range 3.170 - 26.41
Shares Outstanding 65,417,547
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients
 
Via Benzinga
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients
From AlloVir, Inc.
Via Business Wire

Performance

YTD
-70.93%
-70.93%
1 Month
+1.55%
+1.55%
3 Month
-45.72%
-45.72%
6 Month
-70.23%
-70.23%
1 Year
-79.78%
-79.78%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
AlloVir Reports First Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
Recap: AlloVir Q4 Earnings
Via Benzinga
90 Biggest Movers From Yesterday
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
55 Biggest Movers From Friday
Via Benzinga
53 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps Around 300 Points; AlloVir Shares Spike Higher
Via Benzinga
Mid-Day Market Update: Nasdaq Down Over 150 Points; Netflix Shares Drop Following Earnings Report
Via Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Is AlloVir (ALVR) Stock Up 30% Today?
Via InvestorPlace
Mid-Morning Market Update: Markets Mixed; Dow Jumps 250 Points
Via Benzinga
Why AlloVir Stock Is Surging Today
Via Benzinga
The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients
From AlloVir
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
AlloVir Appoints Shawn Tomasello to Its Board of Directors
From AlloVir
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients
From AlloVir
Via Business Wire
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
From AlloVir
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.